SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Newcastle Upon Tyne, Northumberland and currently employs 15 full-time employees. The company went IPO on 2017-04-05. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health, and commercialization of these technologies, as well as the manufacture and sales of dermatological products through acquired entities. Its segments include UK, US, EU, and RoW. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The company targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis-a chronic inflammatory condition of the skin.